Astera Labs (ALAB) has dropped 18.6% in five days to $234.53, and the balance of evidence for the next two to six weeks leans negative, with high conviction. The stock is 39.8% below its October 6, 2026 close of $389.80, it trails both the S&P 500 and the semiconductor ETF SOXX, and it sits under its 40-week average. Earnings are due today, November 3, 2026, so the next move will show whether this was a reset or a breakdown.
Why it matters
No company-specific news in our feed explains this fall, so the move cannot be pinned on one headline. What we can say is that ALAB has gone from $389.80 on October 6 to $234.53, a one-month loss of 33.4%, and that it arrives at an earnings report today, November 3, with the stock 51.45% below its 52-week high of $483.02. Today's session brought a 2.12% bounce, and SOXX rose 2.41%, so the rebound looks like part of a sector move rather than a verdict on ALAB.
Much of the damage is already in the price. The stock is still up 40.2% year to date and 15.1% over six months, and it sits 133.9% above its 52-week low of $100.27. That means holders from earlier in the year are still ahead, which leaves room for further selling if the report disappoints. Volume today is 27.5% below its 20-day average, so the latest bounce comes on thin participation, and a bounce on thin volume is weak evidence that buyers have returned.
The five-day numbers show where the weakness sits. ALAB fell 18.6%, SOXX fell 9.4% and SPY fell 2.1%. The broad market explains very little of that. The semiconductor group accounts for about half of the drop, and the stock fell a further 9.2 percentage points beyond its sector. The longer view says the same: over 50 days ALAB lags the S&P 500 by 22.0 points and SOXX by 12.8 points. This is a stock-specific problem on top of a weak sector.
We have no articles to cite on either side of the argument, so the debate shows up in the analyst numbers instead. Twenty-one analysts rate the stock a consensus buy, with a mean price target of $387.57, and the shares trade 39.5% below that. The targets run from $190 to $500. The most cautious analyst sits almost exactly on the $189.75 support zone that the price map shows below, so even the low end of the Street's range is not far under today's price. The optimistic camp argues that the October peak was fair value and the drop is an overreaction. The market, at a $40.7 billion valuation, is currently voting the other way.
What the evidence says
For the long term, the thesis is weakened and the stock is in a corrective phase. Price is below its 40-week average, so the weekly trend is down, and the 50-day average at $306.15 sits well above the price. The 200-day average at $255.77 is also overhead. The year-to-date gain keeps this from being a full break of the larger advance, but a stock that has lost close to 40% in under a month has not shown that the advance is intact.
For the next two to six weeks, the balance of evidence leans negative, and conviction is high at 3 of 4 points. Three things carry it. The daily trend runs with the weekly downtrend, so the two timeframes agree. The stock lags the S&P 500 by 22.0 points over 50 days. And it lags SOXX by 12.8 points, which means sector weakness alone does not account for it. Price is below both the 10-week and 40-week averages, and the rallies that have appeared so far have run into sellers.
The strongest case against this is that the stock is oversold. The 14-day RSI is 30.77, today's bounce shows buyers will step in near current prices, and the selling came on volume below average. A stock this far from the 50-day average can rebound sharply, and an earnings report that reassures could produce one. Oversold conditions, though, describe how stretched a move is, not that it has ended. The rebound would also first have to clear $250 and then the 200-day average at $255.77, a zone where sellers have already appeared. That is why conviction is high rather than at its maximum, and why the case against does not tip the balance.
Levels that matter
The structure is capped at $250, a round number where sellers have shown up on rallies. Just above it sits the 200-day average at $255.77, then $275. The weekly downtrend would end only on a weekly close above $306.15, the 50-day average. Until price gets there, the stock is lower highs under resistance, not a recovery. Support sits at $225, then $200, then the swing zones at $189.75 and $183.85, with the $100.27 52-week low far below.
The breakout level on the downside is a daily close below $225. From there the math uses a stop at $255.63, which is $250 plus a quarter of the 14-day ATR of $22.53. The targets are $189.75 and $183.85, which give 1.2 to 1 and 1.3 to 1 reward to risk. That does not reach the 3 to 1 that makes a breakout worth the risk. Only a target much further down, toward the $100.27 low, would clear 3 to 1, and there is no support zone between $183.85 and that level. Price is at $234.53, so the breakout has not happened yet.
What would change the picture
A weekly close above $306.15, the 50-day average, would change the picture. That would put price back above the level where the trend ends and show buyers have recovered much of the October loss. The non-price fact that could drive it is today's earnings report: results and an outlook strong enough to reassure the market that the growth story behind the October peak is intact. Without that, a rally is more likely to stall at $250 and the 200-day average.
What to watch
- Earnings, November 3, 2026: the number that matters is the company's forward outlook, because the stock fell 39.8% from its peak on expectations of future growth, not past results.
- Sector moves: SOXX fell 9.4% in five days and is down 21.4% over a month. ALAB has moved harder than the group, so a semiconductor rebound or another leg lower will likely move the stock before its own news does.
- Valuation versus consensus: the mean target of $387.57 is 39.5% above the price, with targets from $190 to $500. The gap shows how far the Street's view is from the market's, and it will narrow either by price rising or by targets being cut.